NovoCure (NVCR) Operating Expenses (2014 - 2026)

NovoCure has disclosed Operating Expenses across 13 years of filings, most recently posting $202.5 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $202.5 million, up 31.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $690.5 million (up 6.8% YoY), and the FY2025 annual result was $642.3 million, up 0.59% from the prior year.
• Operating Expenses came in at $202.5 million for Q1 2026 at NovoCure, up from $172.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $202.5 million in Q1 2026 to a low of $110.6 million in Q1 2022.
• The 5-year median for Operating Expenses is $152.9 million (2023), against an average of $153.5 million.
• Across the five-year window, Operating Expenses soared 38.14% in 2023 and declined 9.69% in 2025, its largest moves.
• NovoCure's Operating Expenses stood at $142.5 million in 2022, then grew by 7.31% to $152.9 million in 2023, then gained by 24.95% to $191.1 million in 2024, then slipped by 9.69% to $172.6 million in 2025, then gained by 17.36% to $202.5 million in 2026.
• The last three Operating Expenses figures came in at $202.5 million (Q1 2026), $172.6 million (Q4 2025), and $158.5 million (Q3 2025), per Business Quant data.